Xeris Biopharma Holdings, Inc.
XERS
$6.96
-$0.22-3.06%
NASDAQ
| 09/30/2025 | 06/30/2025 | ||||
|---|---|---|---|---|---|
| Revenue | 3.97% | 19.00% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | 3.97% | 19.00% | |||
| Cost of Revenue | -7.58% | 36.32% | |||
| Gross Profit | 6.28% | 16.05% | |||
| SG&A Expenses | 4.65% | 0.85% | |||
| Depreciation & Amortization | 0.00% | 0.04% | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 0.88% | 6.09% | |||
| Operating Income | 50.18% | 245.05% | |||
| Income Before Tax | 132.21% | 79.09% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | 132.21% | 79.09% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 132.21% | 79.09% | |||
| EBIT | 50.18% | 245.05% | |||
| EBITDA | 30.09% | 11,666.15% | |||
| EPS Basic | 131.40% | 80.00% | |||
| Normalized Basic EPS | 131.58% | 79.89% | |||
| EPS Diluted | 128.93% | 80.00% | |||
| Normalized Diluted EPS | 128.95% | 79.89% | |||
| Average Basic Shares Outstanding | 2.63% | 4.60% | |||
| Average Diluted Shares Outstanding | 11.39% | 4.60% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||